Granulokine (Filgrastim)

Granulokine is indicated for several clinical situations in which neutrophil counts are low or need to be increased.

• Chemotherapy‑induced neutropenia to reduce the risk of infection.
• Aplastic anemia to support bone‑marrow recovery.
• Mobilization of peripheral blood progenitor cells for stem‑cell collection.
• Preparation for bone‑marrow transplantation to improve engraftment.
• Treatment of severe chronic neutropenia when other therapies are insufficient.

The safety profile of Granulokine includes both frequently observed reactions and less common but potentially serious events.

Common

• Bone pain, especially in the hips, sternum or long bones.
• Mild fever or chills.
• Headache or dizziness.
• Injection‑site erythema or swelling.

Serious

• Splenic rupture or enlargement.
• Acute respiratory distress syndrome.
• Severe allergic reactions such as anaphylaxis.

The clinician should evaluate several precautionary factors before initiating Granulokine therapy to minimize risk.

• Assess baseline neutrophil count and overall bone‑marrow function.
• Use caution in patients with a history of splenic disorders or abdominal trauma.
• Monitor for signs of hypersensitivity during and after administration.
• Adjust dosing in patients with renal impairment as recommended by prescribing information.
• Avoid use in individuals with known hypersensitivity to filgrastim or any excipients.
• Consider pregnancy and lactation status; data are limited, so weigh potential benefits against unknown risks.

Granulokine may interact with other medications, affecting its efficacy or safety profile.

Avoid

• Concurrent use with chemotherapy agents that cause profound myelosuppression without appropriate timing.
• Combination with other colony‑stimulating factors (e.g., sargramostim) unless specifically directed.

Use with caution

• Antimicrobial agents such as penicillins that may mask infection signs.
• Corticosteroids, which can alter neutrophil dynamics.
• Immunosuppressive drugs that could modify the expected rise in neutrophil counts.